MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

BACKGROUND: Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches. The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces apoptosis in tumours with amplified MDM2 gene and overexpression of MDM2 protein. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohnstad, Hege O, Paulsen, Erik B, Noordhuis, Paul, Berg, Marianne, Lothe, Ragnhild A, Vassilev, Lyubomir T, Myklebost, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128006/
https://www.ncbi.nlm.nih.gov/pubmed/21624110
http://dx.doi.org/10.1186/1471-2407-11-211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128006/
https://www.ncbi.nlm.nih.gov/pubmed/21624110
http://dx.doi.org/10.1186/1471-2407-11-211

Ejemplares similares